Prime Medicine, Inc. (PRME)

US — Healthcare Sector
Peers: BEAM  CRBU  NTLA  SANA  RPHM  DNA  OCEA  RPRX  EDIT  CRSP  VERV  THRX  LIFE  RLAY  IPSC  BPMC 

Automate Your Wheel Strategy on PRME

With Tiblio's Option Bot, you can configure your own wheel strategy including PRME - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PRME
  • Rev/Share 0.318
  • Book/Share 0.8169
  • PB 1.4444
  • Debt/Equity 1.1331
  • CurrentRatio 4.7762
  • ROIC -0.6863

 

  • MktCap 154927451.0
  • FreeCF/Share -0.8512
  • PFCF -1.3906
  • PE -0.7645
  • Debt/Assets 0.3692
  • DivYield 0
  • ROE -1.2505

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade PRME Citigroup Buy Neutral -- $1.5 May 27, 2025
Downgrade PRME H.C. Wainwright Buy Neutral -- -- May 20, 2025
Downgrade PRME JP Morgan Overweight Neutral -- -- May 20, 2025
Initiation PRME JMP Securities -- Mkt Outperform -- $10 Dec. 10, 2024

News

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
PRME
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --

Read More
image for news Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
PRME
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --

Read More
image for news Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
PRME
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative

Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.44 per share a year ago.

Read More
image for news Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
PRME
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

-- Initial data from Phase 1/2 trial of PM359 for p47 phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson's Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 -- CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended March 31, 2025 and provided a business update.

Read More
image for news Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference
PRME
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass. , Feb. 24, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D.

Read More
image for news Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

About Prime Medicine, Inc. (PRME)

  • IPO Date 2022-10-20
  • Website https://www.primemedicine.com
  • Industry Biotechnology
  • CEO Dr. Jeremy S. Duffield M.D., Ph.D.
  • Employees 214

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.